Exai Bio is an orphan non-coding RNAs and AI-based liquid biopsy company.
Exai Bio has raised $67.5M in total funding. The most recent round was Series A. The last funding was announced in December 2021.
Exai Bio's investors include S32, Two Sigma Ventures, Casdin Capital.
Exai Bio is headquartered in Palo Alto, United States.
Exai Bio is an orphan non-coding RNAs and AI-based liquid biopsy company.
Exai Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Exai Bio — Funding & Investors." VCBacked, December 9, 2021, https://www.vcbacked.co/company/exai-bio. Accessed September 30, 2026.
VCBacked. (2021). Exai Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/exai-bio
{{cite web |title=Exai Bio — Funding & Investors |url=https://www.vcbacked.co/company/exai-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated